CD34 and Friedreich ataxia: Herein, we report for the first time the impact of EPAG in an FA patient with mosaicism and two additional FA patients who received lentiviral mediated gene therapy in the FANCOLEN-I trial (NCT03157804) and had been infused with a very low dose of transduced CD34+ cells.